HIV-1 CN54 Gag蛋白与DNA疫苗联合免疫策略研究  

Immunity strategy induced by HIV-1 CN54 Gag protein combined with DNA vaccine

作　　者：闫冬梅[1] 梁立春[1] 王晓玲[1] 林跃智[2] 刘沙[2] 邵一鸣 

机构地区：[1]佳木斯大学基础医学院免疫教研室,黑龙江佳木斯154002 [2]中国疾病预防控制中心性病艾滋病预防控制中心病毒免疫室,北京100050

出　　处：《黑龙江医药科学》2005年第3期9-11,共3页Heilongjiang Medicine and Pharmacy

摘　　要：目的:通过蛋白疫苗与DNA疫苗联合免疫效果的分析,探讨这种免疫方案的优势。方法:用DNA质粒PVRC2000-syngag,在0,2,4周初始免疫BALB/c小鼠,在第6周用HIV-1CN54Gag蛋白加强免疫,每间隔两周采小鼠尾血作结合抗体滴度变化的检测,在第10周处死小鼠,检测小鼠的体液和细胞免疫水平。结果:小鼠在第1次免疫后两周就产生了特异性的结合抗体,抗体在4周开始快速增长,在Gag蛋白加强后两周达到最高峰,之后开始缓慢下降。这种联合免疫组诱导出了细胞免疫和体液免疫,抗体亚型检测倾向于Th2型体液免疫。结论:本实验为提高亚单位疫苗免疫原性提供了新的免疫方法。为免疫策略的深入研究奠定了一定的基础,提供了一定的数据支持和启示。Objective:To study the advantage of the immunity strategy by immunogenicity analysis of the vaccination regimen consisting of priming with DNA vaccine and boosting with HIV-1 CN54 Gag protein. Methods: BALB/C mice were immunized with DNA vaccine at weeks 0, 2 and 4 , and with Gag protein at week 6. Blood sample were collected every two weeks , then antibodies against HIV were detected. Some mice were killed and cellular immune responses were examined with flow cytometer at 10 week. Results: In mice pvrs2000-syngag/gag p55 group, HIVspecific antibodies emerged at week 2 and increased at week 4, and the antibodies achieves peak until the mice immunized with gag p55 and then declined after week 8. Cellular immune responses and humoral immune were all detected in pvrs2000-syngag/gag p55 group . Conclusion: Our study provides a new method for improving the immunogencity of gag protein, and has established a foundation for developing immunity strategy for Chinese HIV, with data and enlightenment provided.

关 键 词：亚单位疫苗 初免-加强免疫 免疫策略 流式细胞仪 

分 类 号：R392.11[医药卫生—免疫学]